Skip to main content

Table 5 Toxicity profile for the NSCLC with brain metastasis patients treated by CRT and RT

From: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Side effects/N (%)

RCT arm (N = 129)

RT arm (N = 109)

P for all grades

P for grade III/IV

All grades

Grade III/IV

All grades

Grade III/IV

Fatigue

81 (62.8)

16 (12.4)

68 (62.4)

12 (11.0)

0.95

0.74

Anorexia

64 (49.6)

14 (10.9)

47 (43.1)

9 (8.3)

0.29

0.50

Diarrhea

18 (13.9)

0 (0%)

12 (11.0)

0 (0%)

0.50

NA

Nausea

88 (68.2)

29 (22.5)

83 (76.1)

20 (18.3)

0.18

0.43

Vomiting

69 (53.5)

14 (10.9)

61 (56.0)

13 (11.9)

0.70

0.80

Headache

55 (42.6)

13 (10.1)

43 (39.4)

11 (10.1)

0.62

0.99

Anemia

72 (55.8)

5 (3.9)

61 (56.0)

3 (2.8)

0.98

0.91

Neutropenia

66 (51.2)

13 (10.1)

59 (54.1)

10 (9.2)

0.65

0.81

Thrombocytopenia

61 (47.3)

4 (3.1)

51 (46.8)

2 (1.8)

0.94

0.84